News
2022
-
Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Seventh Consecutive Year
-
【Conference presentation】Presenting the Most Recent Data at the 15th Clinical Trials on Alzheimer’s Disease：CTAD
-
Sysmex receives the highest rating of GOLD in the Pride Index 2022, for its efforts related to sexual and gender minorities
-
Business Results Announcement for the First Six Months of the Fiscal Year Ending March 31, 2023 (See Latest Financial Statements)
-
Sysmex Receives “Chairman's Prize from the Hyogo Institute of Invention and Innovation” and “Encouragement Prize for Invention” in 2022 “Kinki Local Commendation for Inventions”
-
Sysmex Publishes Sysmex Report 2022 (Integrated Report) and the Sysmex Sustainability Data Book 2022
-
Implementing the Group-wide Unified Social Contribution Activity “Sysmex Gives Back Campaign”
-
Medicaroid Receives MHLW Approval for the Use of the hinotori™ Surgical Robot System in Gastroenterology and Gynecology
-
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
-
Business Results Announcement for the First Three Months of the Fiscal Year Ending March 31, 2023 (See Latest Financial Statements)
-
【Conference presentation】Presenting the Most Recent Data at the Alzheimer's Association International Conference(AAIC) 2022
-
【Publication of a paper】Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
-
Sysmex Again Selected for Inclusion in All ESG Indices adopted by the GPIF
-
Posted Company Briefing Presentation for Our Stakeholders
-
Receipt of the “Invention Prize” in 2022 National Commendation for Invention
-
The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana
-
Sysmex Europe SE and Sysmex Inostics GmbH launch two CE-IVD certified Plasma-SeqSensei™ liquid biopsy kits: Solid Cancer IVD Kit and Breast Cancer IVD Kit
-
Business Results Announcement for the Fiscal Year Ended March 31, 2022 (See Latest Financial Statements)
-
Sysmex Selected for Inclusion in the “FTSE Blossom Japan Sector Relative Index”
-
Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer’s Disease
-
Posted the 19th Technology Presentation
-
Implementing the Group-wide Unified Social Contribution Activity “Sysmex Gives Back Day”
-
Business Results Announcement for the First Nine Months of the Fiscal Year Ending March 31, 2022 (See Latest Financial Statements)
